{"id":"fluarix-tetra","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site soreness"},{"rate":"5-10","effect":"Injection site erythema"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL36985","moleculeType":"Small molecule","molecularWeight":"800.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) influenza virus particles representing four seasonal flu strains (two influenza A and two influenza B). When administered, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells that recognize and neutralize circulating influenza viruses during the flu season.","oneSentence":"Fluarix Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:49.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT04381689","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-23","conditions":"Healthy","enrollment":245},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT06336317","phase":"PHASE4","title":"Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-24","conditions":"Acute Myocardial Infarction, Cardiovascular Diseases, Inflammatory Response","enrollment":90},{"nctId":"NCT06824779","phase":"PHASE4","title":"Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-12-05","conditions":"Volunteers, Flu Vaccine","enrollment":30},{"nctId":"NCT06694025","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-10-01","conditions":"Immunization, Influenza (Healthy Volunteers)","enrollment":670},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT05513391","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-10","conditions":"Influenza Immunization","enrollment":366},{"nctId":"NCT06141655","phase":"PHASE4","title":"HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia","status":"COMPLETED","sponsor":"Federico Martinón Torres","startDate":"2023-10-26","conditions":"Influenza","enrollment":134476},{"nctId":"NCT06582277","phase":"PHASE2","title":"Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836","status":"COMPLETED","sponsor":"Osivax","startDate":"2024-10-22","conditions":"Vaccine-Preventable Diseases, Influenza","enrollment":117},{"nctId":"NCT05585983","phase":"PHASE4","title":"INfluenza VaccInation To Mitigate typE 1 Diabetes","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-12-14","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT05110911","phase":"","title":"Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-04-02","conditions":"Influenza, Human, SARS-CoV-2 Infection","enrollment":1500},{"nctId":"NCT05648357","phase":"PHASE4","title":"A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-12-14","conditions":"Influenza, Human","enrollment":250},{"nctId":"NCT06716567","phase":"PHASE4","title":"Maternal Determinants of Immunity to Influenza","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2020-11-16","conditions":"Vaccination; Infection, Maternal-Fetal Relations, Influenza","enrollment":109},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT05415462","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-06","conditions":"Seasonal Influenza","enrollment":6102},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT03160118","phase":"PHASE4","title":"Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-03-27","conditions":"Prevention of Influenza","enrollment":20},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT02663102","phase":"","title":"Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-20","conditions":"Influenza, Human","enrollment":1388},{"nctId":"NCT03735147","phase":"PHASE4","title":"Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2018-10-23","conditions":"Influenza Vaccines","enrollment":12},{"nctId":"NCT06341374","phase":"","title":"Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients","status":"RECRUITING","sponsor":"Parc Taulí Hospital Universitari","startDate":"2023-11-06","conditions":"Apnea, Obstructive Sleep, SARS CoV 2 Infection","enrollment":50},{"nctId":"NCT05781191","phase":"","title":"Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-11-13","conditions":"Influenza, COVID-19","enrollment":8231},{"nctId":"NCT06304038","phase":"","title":"Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2017-10-16","conditions":"Influenza Vaccine, Cost-Benefit Analysis","enrollment":5483},{"nctId":"NCT06286488","phase":"PHASE4","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2020-09-15","conditions":"Influenza, Obesity, Pregnancy; Infection","enrollment":1500},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT03688620","phase":"PHASE4","title":"Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-10-05","conditions":"Influenza, Human","enrollment":1060},{"nctId":"NCT05129436","phase":"","title":"Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI)","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2020-10-10","conditions":"Seasonal Influenza Vaccination","enrollment":20},{"nctId":"NCT05739474","phase":"PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children","status":"UNKNOWN","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2022-01-19","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":948},{"nctId":"NCT05996549","phase":"PHASE4","title":"Cost-effectiveness of the Influenza Vaccination","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-09-29","conditions":"Influenza Vaccine, Cost-Effectiveness, Vaccination","enrollment":2567},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":"Influenza, Herpes Zoster","enrollment":148},{"nctId":"NCT05869201","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-10-06","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":450},{"nctId":"NCT03930017","phase":"","title":"Pregnancy, Arsenic and Immune Response","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-10-14","conditions":"Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired","enrollment":784},{"nctId":"NCT05308212","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2021-03-04","conditions":"Influenza","enrollment":633},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":"Influenza, Vaccines","enrollment":1600},{"nctId":"NCT04222595","phase":"NA","title":"FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-10-16","conditions":"Immunization","enrollment":33},{"nctId":"NCT05315024","phase":"NA","title":"Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-30","conditions":"Influenza","enrollment":72},{"nctId":"NCT05152017","phase":"PHASE1","title":"The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2019-11-16","conditions":"Influenza","enrollment":75},{"nctId":"NCT02831608","phase":"PHASE4","title":"Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis","status":"COMPLETED","sponsor":"Ole Frobert, MD, PhD","startDate":"2016-10","conditions":"Myocardial Infarction, Influenza, Human, Influenza Vaccines","enrollment":2571},{"nctId":"NCT04848467","phase":"PHASE3","title":"COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2021-10-01","conditions":"SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)","enrollment":""},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT02768805","phase":"PHASE2","title":"Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-03-02","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":900},{"nctId":"NCT03278067","phase":"","title":"Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-12","conditions":"Influenza, Human","enrollment":23939},{"nctId":"NCT02831751","phase":"PHASE2","title":"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-04","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":1001},{"nctId":"NCT03104790","phase":"PHASE4","title":"Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls","status":"COMPLETED","sponsor":"Public Health England","startDate":"2017-10-02","conditions":"Influenza Vaccination, Influenza, Vaccination","enrollment":373},{"nctId":"NCT03718468","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2018-10-30","conditions":"Influenza","enrollment":842},{"nctId":"NCT02893878","phase":"","title":"Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-12","conditions":"Influenza, Human","enrollment":19334},{"nctId":"NCT01439360","phase":"PHASE3","title":"An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":"Influenza","enrollment":12046},{"nctId":"NCT01878812","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-11","conditions":"Influenza","enrollment":117},{"nctId":"NCT03654937","phase":"PHASE4","title":"Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2016-09-01","conditions":"Influenza Virus Vaccine Adverse Reaction, Influenza Vaccine Allergy","enrollment":45},{"nctId":"NCT03630523","phase":"NA","title":"Response of Immune System to Flu Vaccination in PHTS","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2018-10","conditions":"PTEN Hamartoma Tumor Syndrome","enrollment":30},{"nctId":"NCT02207413","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-18","conditions":"Influenza","enrollment":1886},{"nctId":"NCT01954251","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-03","conditions":"Herpes Zoster","enrollment":829},{"nctId":"NCT03502291","phase":"PHASE4","title":"The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study","status":"COMPLETED","sponsor":"Liverpool University Hospitals NHS Foundation Trust","startDate":"2015-08","conditions":"Pneumonia, Influenza, Human","enrollment":324},{"nctId":"NCT02218697","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-01","conditions":"Influenza","enrollment":357},{"nctId":"NCT02369341","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-29","conditions":"Influenza","enrollment":121},{"nctId":"NCT02266992","phase":"PHASE2","title":"Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2014-09","conditions":"Acquired Immune Deficiency Syndrome Virus","enrollment":28},{"nctId":"NCT02658409","phase":"PHASE3","title":"A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study","status":"UNKNOWN","sponsor":"Green Cross Corporation","startDate":"2015-11","conditions":"Influenza","enrollment":1630},{"nctId":"NCT02557802","phase":"NA","title":"T-cell Diversity Following Intranasal and Intramuscular Vaccines","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2015-10","conditions":"Influenza","enrollment":30},{"nctId":"NCT02148328","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2014-05","conditions":"Influenza","enrollment":240}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ANAPHYLACTIC REACTION"},{"count":3,"reaction":"COVID-19"},{"count":2,"reaction":"ABDOMINAL DISTENSION"},{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"ANOGENITAL WARTS"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":2,"reaction":"HYPERTENSION"},{"count":2,"reaction":"HYPOTENSION"},{"count":2,"reaction":"INFLUENZA"}],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FLU D-QIV (GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra)","Influsplit™ Tetra","Licensed quadrivalent inactivated seasonal influenza vaccine","Fluarix Quadrivalent"],"phase":"phase_3","status":"active","brandName":"Fluarix Tetra","genericName":"Fluarix Tetra","companyName":"University of Surrey","companyId":"university-of-surrey","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fluarix Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}